Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/555105cb-5a62-4703-91b8-b419ded90f2c/

CPRX

Catalyst Pharmaceuticals Inc
Chart
31.49 USD
Latest Week 2026-07-17
Snapshot 2026-07-26 · 1.0w · Fresh
0.73
OS Score
31.0%
Value
94.0%
Quality
85.0%
Momentum
5/9
F-Score
0.540
QV
Strategy Eligibility
6 of 23 passing
OS Composite
Trending Value
Quality × Value
🏛
Cornerstone Value
🌿
Cornerstone Growth
💎
Deep Value
VC2 Cheapest
📐
EBITDA/EV
9.9%
Veiled Value
Piotroski Bargains
🔬
Quality Compounders
📈
Consistent Earners
Yes
🌱
GARP
🔄
Shareholder Yield
💰
High Yield
🚀
Momentum Leaders
12-1 49%
Market Leaders
Tiny Titans
🔍
Small Cap Value
🛡
Low Volatility
Vol 22%
🏷
Sector Cheapest
🧠
Capital Allocators
CAQ 0.87
Risk-Adj Momentum
RAM 2.22
V
Value Analysis
Cheapness relative to fundamentals
31.0%ile
P/E
17.4×
P/S
6.5×
P/B
3.8×
E/P
0.0863
FCF Yield
0.067
EBITDA/EV
0.099
SH Yield
0.010
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
79.00000000
/100 — 1=cheapest
VC2 (Trending Value)
79.00000000
/100
VC3 (Buyback)
80.00000000
/100
FCF yield of 6.7% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
94.0%ile
ROE
0.219
ROA
0.193
Net Margin
0.371
Op Margin
0.448
GPA
0.447
Current
7.10
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Stability
0.148
lower=better
Accruals
0.011
lower=better
5yr Consist
Yes
ROE of 22% is exceptional.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
85.0%ile
6M Return
38.7%
12M Return
49.7%
12-1 Mom
49.2%
Risk-Adj
2.22
Vol 252d
22.2%
Vol 60d
48.5%
↑ Expanding
Max DD 12M
-7.6%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 49% is very strong — a clear uptrend. Risk-adjusted momentum of 2.22 is excellent — strong returns relative to volatility. Near-term vol (49%) is expanding vs long-term (22%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.73
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
Sector Context
Healthcare · 500 peers
Sector Value %ile
9.0%
Sector Quality %ile
93.4%
P/E z-score
-0.16
P/B z-score
-0.13
Sector Avg OS
64.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
MD Mednax Inc 97.0% 86.0% 84.0% 94.0%
Factor Interactions
Quality Momentum — Expensive
Strong quality (94th) and momentum (85th) but expensive (31th value). Premium priced — watch for mean reversion.
Volatility Expanding
60-day vol (49%) significantly exceeds 252-day (22%). Near-term risk is elevated.
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
C
54.0% avg (7 factors)
Quality
A
86.2% avg (7 factors)
Momentum
A
88.5% avg (4 factors)
Risk
A
79.7% avg (1 factors)
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.730—6
Value %ile0.310—0
Quality %ile0.940—8
Momentum %ile0.850—6
F-Score5.000—0
Confidence0.812—8
Volatility0.222—0
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
17.42
Earnings Yield (E/P)
0.0863
Price / Sales
6.46
Price / Book
3.81
Price / Cash Flow
18.51
FCF Yield
6.7%
EBITDA / EV
9.9%
Sales Yield (1/P·S)
0.1925
Shareholder Yield
Div + net buyback / mktcap
1.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
21.9%
Return on Assets
19.3%
Net Margin
37.1%
Operating Margin
44.8%
Gross Profit / Assets
Novy-Marx GPA
44.7%
Current Ratio
7.10
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.011
External Financing
Net issuance — lower=better
0.035
MomentumPrice trend strength over different horizons
6M Return
38.7%
12M Return
49.7%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
49.2%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
2.22
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Earnings Stability (CV)
Lower = more stable
0.148
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
5
Buyback Yield
1.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
79
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
79
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
80
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity